MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

319.58

01-November-24 15:59:58

15 minutes delayed

Stocks

+60.24

+23.23%

Today's range

262.85 - 321.19

ISIN

N/A

Source

NASDAQ

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 Nov 2023 08:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 Sep 2023 22:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Proposed Public Offering

28 Sep 2023 16:01:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 Sep 2023 16:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 Sep 2023 09:10:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 Aug 2023 08:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 Jul 2023 08:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 Jun 2023 08:00:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 Jun 2023 03:30:00 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 Jun 2023 08:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

01 Jun 2023 08:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

11 May 2023 08:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 May 2023 08:00:02 By Nasdaq GlobeNewswire
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 Feb 2023 08:00:02 By Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 Feb 2023 08:00:01 By Nasdaq GlobeNewswire
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.